Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

Background Approximately 188 million people use cannabis yearly worldwide, and it has
recently been legalised in 11 US states, Canada, and Uruguay for recreational use. The …

As countries adopt more permissive cannabis policies, it is increasingly important to identify
strategies that can reduce the harmful effects of cannabis use. This study aimed to determine …

Importance Controlled clinical laboratory studies have shown that cannabidiol (CBD) can
sometimes attenuate or exacerbate the effects ofΔ9-tetrahydrocannabinol (Δ9-THC). No …

The recent liberalisation of cannabis regulation has increased public and scientific debate
about its potential benefits and risks. A key focus has been the extent to which cannabidiol …

Background: On the current psychopharmacological panorama, the variety of substances
able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic …

Abstract Background and Aims Cannabis products are becoming increasingly diverse, and
vary considerably in concentrations of∆ 9‐tetrahydrocannabinol (THC) and cannabidiol …

Importance Ketamine hydrochloride is increasingly used to treat depression and other
psychiatric disorders but can induce schizophrenia-like or psychotomimetic symptoms …

Access to cannabis and cannabinoid products is increasing worldwide for recreational and
medicinal use. Two primary compounds within cannabis plant matter, Δ 9 …

The Cannabis plant contains numerous components, including cannabinoids and other
active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid …